PGMS-pathway control state

From Bioblast
Revision as of 13:16, 21 April 2016 by Lamberti Giorgia (talk | contribs) (Created page with "{{MitoPedia |abbr=PGMS |description=left|200px|PGMS '''PGMS''': Pyruvate & Glutamate & Malate & Succinate. '''MitoPathway control:''' CI&II 2...")
(diff) ← Older revision | Latest revision (diff) | Newer revision β†’ (diff)


high-resolution terminology - matching measurements at high-resolution


PGMS-pathway control state

Description

PGMS

PGMS: Pyruvate & Glutamate & Malate & Succinate.

MitoPathway control: CI&II


2-oxoglutarate is produced through the citric acid cycle from citrate by isocitrate dehydrogenase, from oxaloacetate and glutamate by the transaminase, and from glutamate by the glutamate dehydrogenase. If the 2-oxoglutarate carrier does not outcompete these sources of 2-oxoglutarate, then the TCA cycle operates in full circle with external pyruvate&malate&glutamate&succinate

Abbreviation: PGMS

Reference: Gnaiger 2014 MitoPathways - Chapter 5.6





MitoPedia O2k and high-resolution respirometry: "SUIT state" is not in the list (O2k hardware, DatLab, Oroboros QM, O2k-Open Support, O2k-Respirometry, O2k-FluoRespirometry) of allowed values for the "MitoPedia O2k and high-resolution respirometry" property. SUIT state"SUIT state" is not in the list (O2k hardware, DatLab, Oroboros QM, O2k-Open Support, O2k-Respirometry, O2k-FluoRespirometry) of allowed values for the "MitoPedia O2k and high-resolution respirometry" property. 



PGMS(L)

PGMS(P)

PGMS(E)

Discussion

Recent studies showed that CII- and CI&II-linked OXPHOS capacity is inhibited by 2 mM malate concentrations as applied in most SUIT protocols. This inhibition is less pronounced at 0.5 mM malate

Cookies help us deliver our services. By using our services, you agree to our use of cookies.